Miceli R, Tomasello G, Bregni G, Bartolomeo MD, Pietrantonio F. Adjuvant chemotherapy for gastric cancer: Current evidence and future challenges. World J Gastroenterol 2014; 20(16): 4516-4525 [PMID: 24782604 DOI: 10.3748/wjg.v20.i16.4516]
Corresponding Author of This Article
Rosalba Miceli, PhD, Unit of Medical Statistics, Biometry and Bioinformatics, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy. rosalba.miceli@istitutotumori.mi.it
Research Domain of This Article
Oncology
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Apr 28, 2014; 20(16): 4516-4525 Published online Apr 28, 2014. doi: 10.3748/wjg.v20.i16.4516
Adjuvant chemotherapy for gastric cancer: Current evidence and future challenges
Rosalba Miceli, Gianluca Tomasello, Giacomo Bregni, Maria Di Bartolomeo, Filippo Pietrantonio
Rosalba Miceli, Unit of Medical Statistics, Biometry and Bioinformatics, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy
Gianluca Tomasello, Medical Oncology Division, Azienda Istituti Ospitalieri di Cremona, 26100 Cremona, Italy
Giacomo Bregni, Maria Di Bartolomeo, Filippo Pietrantonio, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy
Author contributions: All authors gave substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; drafting the article and critical review for important intellectual content; and final approval of the version to be published.
Correspondence to: Rosalba Miceli, PhD, Unit of Medical Statistics, Biometry and Bioinformatics, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy. rosalba.miceli@istitutotumori.mi.it
Telephone: +39-22-3903198 Fax: +39-22-3902095
Received: November 15, 2013 Revised: January 9, 2014 Accepted: January 19, 2014 Published online: April 28, 2014
Core Tip
Core tip: Despite the benefit of adjuvant therapy has been clearly demonstrated, no general consensus has been still reached on the best treatment option. The narrow therapeutic index of adjuvant chemotherapy requires a careful assessment of expected risks and benefits for individual patients. Many issues, such as the role of postoperative radiotherapy and the best chemotherapy regimen, are still under investigation. Moreover, no prognostic or predictive factors beyond pathological stage have been prospectively validated. Despite researchers’ efforts, this issue still represent an unmet medical need. In this review we describe the recently completed landmark studies and meta analyses, and we discuss the future challenges in this research field.
